Erythropoietin for Management of Anemia Caused by Chemotherapy
This is a phase Ⅱ study of erythropoietin for management of anemia caused by chemotherapy in patients with Diffuse Large B-cell Lymphoma. The investigators want to investigate hematopoietic response of darbepoietin alfa and the quality of life assessment of increasement of hemoglobin.
|Condition or Disease||Intervention/Treatment||Phase|
Darbepoietin alfa may cause the body to make more red blood cells. They are used to treat anemia caused by chemotherapy in patients with malignant lymphoma. Darbepoietin will be applied to R-CHOP(Rituximab, Cyclophosphamide, Adriamycin, Vincristine, Prednisolone) chemotherapy every 21days ± 2days with fixed 360㎍. It will be applied to chemotherapy until increment of hemoglobin 12.0g/dL. If the hemoglobin level exceeds 12.0g/dL, administration of darbepoietin will be temporarily stopped.
And, the questionnaire of the quality of life will be conducted at the baseline, after 2th darbepoietin alfa administration, at study completion.
Arms and Interventions
|Experimental: Darbepoietin alfa|
Hemoglobin level will be checked at every cycle's day 0 or 1(1cycle is 21days) after starting Darbepoietin alfa. It will be applied to chemotherapy until increment of hemoglobin 12.0 g/dL.
Drug: Darbepoetin alfa
Darbepoietin alfa will be administered subcutaneously at a fixed dose of 360㎍. If it is impossible, administration by intravenous infusion is okay.
R-CHOP regimen is a practical procedure in patients with Diffuse Large B-cell Lymphoma. Darbepoietin alfa will be administered to these patients.
Primary Outcome Measures
- Hematopoietic response [hemoglobin level of day 21 after Darbepoietin alfa administration]
Hemoglobin level after Darbepoietin alfa administration
Secondary Outcome Measures
- Quality of life as measured by Functional Assessment of Cancer Therapy Scales for anemia [at baseline, Day 21 after 2th darbepoietin alfa administration, Day 21 after last darbepoietin alfa administration]
- Adverse events as measured by CTCAE v3.0 [From the date of first drug administration to the date of the 30th days of last drug administration.]
- Proportion of patients requiring red blood cell transfusions [From the date of first darbepoietin alfa administration to day 21 after last darbepoietin alfa administration]
- Mean time to response of hemoglobin [From the date of first darbepoietin alfa administration to day 21 after last darbepoietin alfa administration]
Histologically confirmed diffuse large B cell lymphoma treated with R-CHOP(Rituximab, Cyclophosphamide, Adriamycin, Vincristine, Prednisolone) chemotherapy
hemoglobin < 10.0 g/dL are shown at least 3 cycles after starting R-CHOP(Rituximab, Cyclophosphamide, Adriamycin, Vincristine, Prednisolone)
Currently receiving or planning to receive at least 4 times of darbepoetin
Age > 18 years
ECOG(Eastern Cooperative Oncology Group) performance status 0-2
Bilirubin < 2 times upper limit of normal
ALT(alanine aminotransferase) or AST(aspartate aminotransferase) < 5 times upper limit of normal
Creatinine < 2 times upper limit of normal
Ferritin > 20 mcg/L (i.e., not obviously iron deficient)
Can read Quality of life as measured by Functional Assessment of Cancer Therapy Scales for Anemia
Agree with informed consent
Received radiation therapy at least 4 weeks before starting chemotherapy
serious pre-existing medical condition (e.g., cardiac failure [New York Heart Association Class III or IV, or left ventricular ejection fraction <50%], active peptic ulceration, uncontrolled diabetes mellitus, or acute diffuse infiltrative pulmonary disease)
uncontrolled hypertension, defined as systolic blood pressure (BP) ≥ 180 mm Hg and/or diastolic BP ≥ 100 mm Hg, despite medical therapy
arrhythmia NCI CTCAE grade ≥ 2
History of previously treated seizures allowed provided the patient has been seizure-free for a minimum of 3 months
active systemic infection requiring treatment, a known diagnosis of human HIV, or active hepatitis B (hepatitis B carriers were permitted)Malignancy was treated surgically or with local radiation therapy with curative intent and the patient has been disease free for > 3 years
known hypersensitivity to darbepoetin alfa
pregnant or nursing and Negative pregnancy test
previous diagnosis of another malignancy with radiographic or biochemical evidence of residual disease (except completely resected basal cell carcinoma, squamous cell carcinoma of the skin, or an in-situ malignancy)
combined iron deficiency anemia
received erythropoietin at least one months before starting darbepoetin
considered autologous stem cell transplantation before finish 6 cycles of chemotherapy
untreated primary or metastatic CNS(central nervous system) malignancy
Contacts and Locations
LocationsNo locations specified.
Sponsors and Collaborators
- Kosin University Gospel Hospital
Study Documents (Full-Text)None provided.